American journal of cancer research最新文献_第5页

Vulvar dermatofibrosarcoma protuberans: a case series. 外阴隆突性皮肤纤维肉瘤1例。

IF 2.9 3区医学

American journal of cancer research Pub Date : 2025-07-25 eCollection Date: 2025-01-01 DOI: 10.62347/WEKR2445

Chuan Xie, Yangmei Shen

{"title":"Vulvar dermatofibrosarcoma protuberans: a case series.","authors":"Chuan Xie, Yangmei Shen","doi":"10.62347/WEKR2445","DOIUrl":"10.62347/WEKR2445","url":null,"abstract":"Dermatofibrosarcoma protuberans (DFSP) is a rare, superficial low - to intermediate-grade sarcoma that typically presents as an asymptomatic slow-growing indurated dermal plaque. Although DFSP has a relatively high local recurrence rate, distant metastasis is rare. DFSP primarily occurs on the trunk and extremities but is seldom reported in the vulva. Due to its rarity, the clinical characteristics, pathological diagnosis, prognosis, and optimal management of vulvar DFSP remain poorly characterized. We retrospectively analyzed vulvar DFSP cases from our institution (January 2010 - January 2023). Clinical data and follow-up were obtained from hospital records, and imaging studies were reviewed via the picture archiving and communication system. Seven patients were included, with a median symptom-onset age of 44.3 years (range, 27-73). Patients typically presented with firm, asymptomatic masses. The labia majora was most commonly affected (n = 6, 85.7%). Tumor size averaged 4.3 cm (range, 2.0-6.5). All patients underwent excisional biopsy followed by wide local excision; none received lymphadenectomy. Surgical margins were documented in six patients, with negative margins achieved in five after initial wide excision. Over a mean follow-up of 27.3 months (range, 12-54), one patient (14.3%) experienced local recurrence. No recurrence occurred in patients with negative margins. Vulvar DFSP predominantly affects young and middle-aged women, manifesting as vulvar masses of variable size. Wide local excision is the primary treatment. While vulvar DFSP has a propensity for local recurrence, widely negative margins appear protective. Long-term follow-up is recommended to monitor for recurrence.","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 7","pages":"3323-3329"},"PeriodicalIF":2.9,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12344167/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144854212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Erratum: SPOP targets oncogenic protein ZBTB3 for destruction to suppress endometrial cancer. 勘误：SPOP靶向致癌蛋白ZBTB3破坏抑制子宫内膜癌。

IF 2.9 3区医学

American journal of cancer research Pub Date : 2025-07-25 eCollection Date: 2025-01-01 DOI: 10.62347/IVFL8331

Xiaofeng Jin, Jian Wang, Qian Li, Hui Zhuang, Jianye Yang, Zihan Lin, Ting Lin, Zeheng Lv, Liliang Shen, Chunhong Yan, Jingfei Zheng, Jie Zhu, Zhaohui Gong, Chenji Wang, Kun Gao

引用次数: 0

USP13 mediates resistance to Ibrutinib in diffuse large B-cell lymphoma via augmenting FHL1 stabilization. USP13通过增强FHL1稳定介导弥漫性大b细胞淋巴瘤对伊鲁替尼的耐药。

IF 2.9 3区医学

American journal of cancer research Pub Date : 2025-07-15 eCollection Date: 2025-01-01 DOI: 10.62347/IMFU7145

Yun Tao, Haibing Yin, Rong Shen, Song He, Xiaobing Miao

{"title":"USP13 mediates resistance to Ibrutinib in diffuse large B-cell lymphoma via augmenting FHL1 stabilization.","authors":"Yun Tao, Haibing Yin, Rong Shen, Song He, Xiaobing Miao","doi":"10.62347/IMFU7145","DOIUrl":"10.62347/IMFU7145","url":null,"abstract":"Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoid malignancy in the world which is mainly divided to ABC type and GCB type. Ibrutinib benefits patients with ABC subtype DLBCL by inhibiting Bruton's tyrosine kinase (BTK), but there are still a lot of patients who are resistant to Ibrutinib. In this study, we found that post-translational modification played a regulatory role in mediating Ibrutinib resistance in DLBCL. The expression of USP13 was significantly higher in Ibrutinib-resistant U2932 cells compared with Ibrutinib-sensitive WSU-DLCL2 cells, and its expression was further increased both in WSU-DLCL2 and U2932 after exposure to Ibrutinib. USP13 overexpression significantly promoted cell growth and decreased Ibrutinib sensitivity in DLBCL while knockdown of USP13 significantly increased Ibrutinib-induced apoptosis and improved the sensitivity to Ibrutinib. Further studies showed that USP13 interacted with FHL1 and stabilized the expression of FHL1 via deubiquitination, thereby mediating the phosphorylation of ERK1/2, resulting in the decrease expression of Bax and the increase expression of Bcl-xL, thus mediating Ibrutinib resistance in DLBCL. The results of immunohistochemical staining of tumor tissue also indicated that the expression level of USP13 was negatively related to the prognosis of DLBCL patients. These new findings provided an experimental basis for overcoming Ibrutinib resistance in DLBCL and showed that USP13 is a potential therapeutic target and prognostic marker in DLBCL.","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 7","pages":"2932-2948"},"PeriodicalIF":2.9,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12344158/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144854211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 2.9 3区医学

American journal of cancer research Pub Date : 2025-07-15 eCollection Date: 2025-01-01 DOI: 10.62347/GUPU2399

Changtian Yin, Jinpeng Wen, Zhekuan Lv, Lingling Ding, Mojiao Lu, Yawen Guo, Lingli Jin, Xiabin Lan, Qingliang Wen, Chuanming Zheng

{"title":"La-related protein 1 drives malignant progression and epithelial-mesenchymal transition in anaplastic thyroid carcinoma.","authors":"Changtian Yin, Jinpeng Wen, Zhekuan Lv, Lingling Ding, Mojiao Lu, Yawen Guo, Lingli Jin, Xiabin Lan, Qingliang Wen, Chuanming Zheng","doi":"10.62347/GUPU2399","DOIUrl":"10.62347/GUPU2399","url":null,"abstract":"Anaplastic thyroid cancer (ATC) is an extremely aggressive and lethal malignancy characterized by a very short average survival time following diagnosis. Understanding the molecular mechanisms that drive this aggressiveness is vital for developing effective therapies. This study aimed to elucidate the role and function of La-related protein 1 (LARP1) in ATC progression. We quantitatively analyzed LARP1 expression in patient samples and ATC cell lines. Functional assays were performed to investigate LARP1's involvement in cancer-related processes, including inhibition of apoptosis, promotion of cell cycle progression, proliferation, colony formation, migration, and invasion. Our results revealed significantly elevated LARP1 expression in ATC tissues, which may be associated with poor patient prognosis. Experimental data demonstrated that LARP1 enhances oncogenic activities, promoting proliferative and invasive behaviors. These findings provide compelling evidence that LARP1 plays a crucial role in ATC malignancy, offering insights into pathophysiology and potential therapeutic targets.","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 7","pages":"2988-3002"},"PeriodicalIF":2.9,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12344170/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144854228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic value of immunoinflammatory indicators and tumor markers for first-line chemotherapy in patients with non-small cell lung cancer. 免疫炎症指标和肿瘤标志物对非小细胞肺癌患者一线化疗的预后价值。

IF 2.9 3区医学

American journal of cancer research Pub Date : 2025-07-15 eCollection Date: 2025-01-01 DOI: 10.62347/ZBGU2008

Xingyu Zhou, Shuo Wang, Jiahai Shi

{"title":"Prognostic value of immunoinflammatory indicators and tumor markers for first-line chemotherapy in patients with non-small cell lung cancer.","authors":"Xingyu Zhou, Shuo Wang, Jiahai Shi","doi":"10.62347/ZBGU2008","DOIUrl":"10.62347/ZBGU2008","url":null,"abstract":"Objective: To evaluate the prognostic significance of immunoinflammatory indicators and tumor markers in patients with non-small cell lung cancer (NSCLC) undergoing first-line chemotherapy.Methods: This retrospective study included 306 NSCLC patients treated with first-line chemotherapy between January 2022 and January 2023. Clinical data, including demographic information, clinicopathological features, immunoinflammatory markers, and tumor markers, were collected. Survival was analyzed using Kaplan-Meier curves and compared with the log-rank test. Cox proportional hazards models were used to identify factors associated with overall survival (OS). Logistic regression was applied to predict 2-year mortality risk, and model performance was evaluated using receiver operating characteristic curves, area under the curve (AUC), calibration plots, and decision curve analysis.Results: By the end of follow-up, 183 patients had died (mortality rate: 59.80%). Univariate analysis showed that high neutrophil-to-lymphocyte ratio (NLR), high platelet-to-lymphocyte ratio (PLR), low lymphocyte-to-monocyte ratio (LMR), and elevated levels of CEA, CA125, and CYFRA 21-1 were significantly associated with worse prognosis (all P<0.001). Multivariate analysis identified high PLR (HR=1.94, P=0.041) and high CEA (HR=2.13, P=0.002) as independent risk factors, while high LMR (HR=0.52, P=0.043) was protective. A logistic model combining CEA, PLR, and LMR showed high predictive accuracy for 2-year mortality (AUC=0.926).Conclusion: Combined assessment of immunoinflammatory and tumor markers improves prognostic accuracy in NSCLC patients receiving first-line chemotherapy and may guide individualized treatment strategies.","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 7","pages":"3209-3218"},"PeriodicalIF":2.9,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12344157/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144854232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative outcomes of transurethral resection of the prostate and prostate kinetic resection in treating benign prostatic hyperplasia with prostatic stones. 经尿道前列腺电切术与前列腺动力电切术治疗良性前列腺增生伴前列腺结石的疗效比较。

IF 2.9 3区医学

American journal of cancer research Pub Date : 2025-07-15 eCollection Date: 2025-01-01 DOI: 10.62347/UOPJ3870

Zuowei Li, Jiahao Lin, Hang Guo, Wenxiong Song, Chao Deng, Dongliang Yan

{"title":"Comparative outcomes of transurethral resection of the prostate and prostate kinetic resection in treating benign prostatic hyperplasia with prostatic stones.","authors":"Zuowei Li, Jiahao Lin, Hang Guo, Wenxiong Song, Chao Deng, Dongliang Yan","doi":"10.62347/UOPJ3870","DOIUrl":"10.62347/UOPJ3870","url":null,"abstract":"Aims: To compare the clinical outcomes of transurethral bipolar plasma enucleation (TBPE) and transurethral resection of the prostate (TURP) in patients with benign prostatic hyperplasia (BPH) complicated by prostatic stones.Methods: This retrospective study included 150 patients divided into TBPE (n = 74) and TURP (n = 76) groups. Perioperative data, urodynamic parameters, symptom scores, complications, and sexual function were evaluated up to 6 months postoperatively.Results: TBPE was associated with shorter catheterization and hospital stay, greater improvements in maximum urinary flow rate, post-void residual volume, and International Prostate Symptom Score, fewer complications, less intraoperative bleeding, and better postoperative sexual function (all P < 0.001). Multivariate analysis confirmed TBPE as an independent predictor of favorable outcomes (OR = 12.074, 95% CI: 6.513-22.386, P < 0.001).Conclusion: TBPE demonstrates superior clinical effectiveness and safety over TURP for managing BPH with prostatic stones.","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 7","pages":"3051-3062"},"PeriodicalIF":2.9,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12344171/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144854170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

HER2-positive, RAS-mutant, MSS colorectal cancer: a rare subtype report and novel insights into immunotherapy and ADC combinations. her2阳性，ras突变，MSS结直肠癌：一种罕见的亚型报告和免疫治疗和ADC联合的新见解

IF 2.9 3区医学

American journal of cancer research Pub Date : 2025-07-15 eCollection Date: 2025-01-01 DOI: 10.62347/GMRV6636

Xiaoyan Kong, Jin Bian, Mingjuan Wang, Wenren Zuo, Qiaoyun Tang, Mengyu Sun, Sheng Qiu, Jianjun Hu

{"title":"HER2-positive, RAS-mutant, MSS colorectal cancer: a rare subtype report and novel insights into immunotherapy and ADC combinations.","authors":"Xiaoyan Kong, Jin Bian, Mingjuan Wang, Wenren Zuo, Qiaoyun Tang, Mengyu Sun, Sheng Qiu, Jianjun Hu","doi":"10.62347/GMRV6636","DOIUrl":"10.62347/GMRV6636","url":null,"abstract":"This study reports a case of HER2-positive, RAS-mutant, microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) exhibiting intrinsic resistance to 5-fluorouracil (5-FU)-based chemotherapy and bevacizumab. Despite multiple lines of prior systemic therapy, the patient achieved significant tumor shrinkage and durable disease control with a combination of PD-1 blockade and a HER2-targeted antibody-drug conjugate (ADC), resulting in a progression-free survival (PFS) exceeding 10 months. Based on this case, we review the current landscape of immunotherapy and ADCs in mCRC, emphasizing the emerging potential of combination strategies for patients harboring rare molecular profiles such as HER2-positive, RAS-mutant MSS tumors. In addition, we discuss the importance of HER2 testing in CRC and the available diagnostic modalities, including immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), next-generation sequencing (NGS), and liquid biopsy. Given the heterogeneity of HER2 expression in CRC, optimizing testing strategies and treatment selection remains a critical research priority. This review underscores the need for large prospective studies and biomarker-driven trials to refine treatment approaches and improve outcomes in this challenging patient population.","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 7","pages":"3150-3163"},"PeriodicalIF":2.9,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12344160/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144854224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Increased autophagy activity suppresses hyperglycemia-related colorectal cancer tumorigenesis both in vitro and in vivo. 体外和体内研究表明，自噬活性增加可抑制高血糖相关结直肠癌的发生。

IF 2.9 3区医学

American journal of cancer research Pub Date : 2025-07-15 eCollection Date: 2025-01-01 DOI: 10.62347/XSRQ4118

Pei-Wen Lin, Yu-Wen Liu, Man-Ling Chu, Chien-An Chu, Chung-Ta Lee, Yao-Hsiang Shih, Sheng-Hui Lan, Shang-Ying Wu, Hong-Yi Chang, Wei-Chung Chen, I-Chen Wu, Li-Tzong Chen, Ming-Yii Huang, Jaw-Yuan Wang, Ying-Ray Lee, Hsiao-Sheng Liu

{"title":"Increased autophagy activity suppresses hyperglycemia-related colorectal cancer tumorigenesis both in vitro and in vivo.","authors":"Pei-Wen Lin, Yu-Wen Liu, Man-Ling Chu, Chien-An Chu, Chung-Ta Lee, Yao-Hsiang Shih, Sheng-Hui Lan, Shang-Ying Wu, Hong-Yi Chang, Wei-Chung Chen, I-Chen Wu, Li-Tzong Chen, Ming-Yii Huang, Jaw-Yuan Wang, Ying-Ray Lee, Hsiao-Sheng Liu","doi":"10.62347/XSRQ4118","DOIUrl":"10.62347/XSRQ4118","url":null,"abstract":"Hyperglycemia contributes to recurrence, poor survival, and drug resistance in colorectal cancer (CRC) patients. Overexpression of G9a (euchromatic histone-lysine N-methyltransferase 2, EHMT2), together with decreased autophagy activity, has been implicated in promoting CRC tumorigenesis and chemoresistance. Here, we demonstrate that high glucose (25 mM) enhances proliferation, focus formation, and migration of CRC cells, while concurrently suppressing autophagy activity. Importantly, pharmacological induction of autophagy increases CRC cell sensitivity to chemotherapeutic agents (5-fluorouracil and oxaliplatin) and attenuates high glucose-induced tumorigenic behaviors. Analysis of CRC patient specimens and data from the TCGA COAD database revealed that LC3, an autophagy marker, is elevated in tumor tissues compared to adjacent normal tissues, and that high LC3 mRNA expression correlates with poor overall survival. Furthermore, enhancing autophagy via the autophagy inducer rapamycin significantly suppressed high glucose-induced tumor formation in a CRC xenograft mouse model. In addition, we identified niclosamide (NC), a repurposed antihelminthic agent, and its derivative niclosamide ethanolamine (NEN), as potential G9a inhibitors and autophagy inducers. NEN dose-dependently suppressed high glucose-activated oncogenic signaling pathways, including β-catenin, c-Myc, STAT3, G9a, and cyclin D1, while restoring autophagy activity. Collectively, our in vitro and in vivo findings strongly support that enhancing autophagy represents a multifaceted strategy to alleviate hyperglycemia, inhibit G9a-mediated signaling, increase chemosensitivity, and suppress high glucose-driven CRC tumorigenesis.","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 7","pages":"2949-2969"},"PeriodicalIF":2.9,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12344155/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144854225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

FOXK1-induced upregulation of NXPH4 predicts poor prognosis and promotes hepatocellular carcinoma progression via PI3K/Akt pathway. foxk1诱导的NXPH4上调可预测不良预后，并通过PI3K/Akt通路促进肝细胞癌进展。

IF 2.9 3区医学

American journal of cancer research Pub Date : 2025-07-15 eCollection Date: 2025-01-01 DOI: 10.62347/ZLOS1416

Yafeng Wang, Zhongqiu Li, Liancai Wang, Yongnian Ren, Deyu Li

{"title":"FOXK1-induced upregulation of NXPH4 predicts poor prognosis and promotes hepatocellular carcinoma progression via PI3K/Akt pathway.","authors":"Yafeng Wang, Zhongqiu Li, Liancai Wang, Yongnian Ren, Deyu Li","doi":"10.62347/ZLOS1416","DOIUrl":"10.62347/ZLOS1416","url":null,"abstract":"Hepatocellular carcinoma (HCC) stands out as a remarkably diverse and complex disease, presenting a myriad of challenges when it comes to predicting prognostic outcomes. Although lactate and branched-chain amino acids (BCAA) are important for the development and progression of various tumors, their function in HCC progression remained largely unclear. The study aimed to identify molecular subtypes in HCC based on lactate metabolism and BCAA metabolism. Clustering 370 HCC patients revealed two distinctive subtypes associated with unfavorable prognosis. Differential expression analysis identified 941 DEGs in lactate metabolism subtypes and 518 in BCAA metabolism subtypes, primarily linked to tumor and metabolism pathways. Prognostic analysis identified 27 LRG-BCAA-DGEs inversely correlated with long-term survival across various cancers. Methylation analysis showed a negative correlation between methylation and mRNA expression of these genes, with limited impact on survival outcomes. NXPH4, dysregulated across tumors, exhibited complex associations with immune cells and prognostic implications in HCC. Functional analysis revealed DEGs associated with endodermal cell differentiation and metabolic pathways. NXPH4 knockdown suppressed HCC cell proliferation, migration, and invasion, indicating its potential as a therapeutic target. Additionally, NXPH4 modulated glucose metabolism via the PI3K/Akt pathway. FOXK1 was identified as a potential transcriptional regulator of NXPH4, suggesting a regulatory axis in HCC tumorigenesis. The study highlights the molecular complexity of HCC, providing insights into potential biomarkers and therapeutic targets.","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 7","pages":"3164-3187"},"PeriodicalIF":2.9,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12344177/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144854223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Methylation status of PAX1 and SF-1: implications for diagnosis and prognosis in endometrial cancer. PAX1和SF-1的甲基化状态：对子宫内膜癌的诊断和预后的影响

IF 2.9 3区医学

American journal of cancer research Pub Date : 2025-07-15 eCollection Date: 2025-01-01 DOI: 10.62347/OAMQ9295

Lei Liang, Bo Yang, Yuanyuan Wu, Jinglei Liu, Rongna Liu, Li Sun

{"title":"Methylation status of PAX1 and SF-1: implications for diagnosis and prognosis in endometrial cancer.","authors":"Lei Liang, Bo Yang, Yuanyuan Wu, Jinglei Liu, Rongna Liu, Li Sun","doi":"10.62347/OAMQ9295","DOIUrl":"10.62347/OAMQ9295","url":null,"abstract":"Endometrial carcinoma (EC) is a common malignancy of the female reproductive system, often diagnosed at advanced stages due to the lack of reliable early biomarkers. Gene methylation has emerged as a key epigenetic mechanism in cancer development, offering potential for early detection and prognostic evaluation. This study aimed to explore the methylation status of Paired Box Gene 1 (PAX1) and Steroidogenic Factor 1 (SF-1) as potential biomarkers for EC diagnosis and prognosis. A total of 110 EC patients and 75 non-EC patients, enrolled between January 2020 and January 2022, were retrospective analyzed using methylation-specific polymerase chain reaction (MSP) to assess the clinical utility of PAX1 and SF-1 methylation in diagnosis, prognosis, and recurrence surveillance. EC patients exhibited significantly higher PAX1 and SF-1 methylation levels compared to controls, with SF-1 methylation showing superior diagnostic efficacy (AUC = 0.735). PAX1 methylation was significantly associated with key clinicopathological features, including tumor differentiation grade (P = 0.001), FIGO staging (P < 0.001), and myometrial invasion depth (P = 0.030). It also showed a strong correlation with overall survival (OS) and cumulative incidence of recurrence (CIF) (P < 0.001). These results highlight the important role of PAX1 methylation in the diagnosis and prognostic evaluation of EC. Multivariate Cox regression analysis identified PAX1 methylation positivity as an independent risk factor for poor prognosis, whereas SF-1 methylation had limited prognostic impact. These findings highlight PAX1 methylation as a valuable biomarker for enhancing diagnostic accuracy and refining prognostic stratification in EC. In contrast, SF-1 methylation primarily contributes to diagnosis. Together, these results offer new insights into the development of personalized diagnostic and therapeutic strategies for EC.","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 7","pages":"3219-3235"},"PeriodicalIF":2.9,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12344154/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144854229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0